摘要
目的:探讨脑裂头蚴病的临床及影像学表现,以提高本病的影像诊断水平。方法:回顾性分析15例手术病理证实的脑裂头蚴病的临床及影像学资料,所有患者均行CT检查,其中行MRI检查者13例。结果:脑裂头蚴病CT表现低密度灶伴点状钙化,不规则或点状强化。MRI可见病灶区有串珠状增强或扭曲的条索样增强影。患者血清免疫学检查均显示曼氏裂头蚴抗体阳性。本组15例中11例在CT定位下行立体定向活检,4例经开颅手术预后均良好。结论:多数脑裂头蚴病的CT和MRI表现具有一定的特征性。血清免疫学检查在诊断脑曼氏裂头蚴病中起到重要作用。
Objective: To study the clinical and imaging manifestations of cerebral sparganosis,so as to improve the accuracy of imaging diagnosis. Methods: The clinical and imaging materials of 15 patients with surgery and pathology proved cerebral sparganosis were retrospectively analyzed. All patients had CT,13 patients had MRI. Results: CT Characteristics of cerebral sparganosis contained low-density lesions with punctuate calcifications,irregular or punctuate intensifications of lesions on the follow-up CT images. MRI showed bead-shaped or tortuous cordlike enhanced images in the region of lesions. The enzyme linked immunosorbent assay for antisparganum antibody was positive in all. Among the 15 cases in this study,11 underwent CT-guided stereotactic biopsy and 4 underwent craniotomy for surgical removal of lesions; all cases have a favorable prognosis. Conclusion: Most of characteristic findings of cerebral sparganosis may observed on CT and MRI. Immunologic examination play significant role in diagnosing cerebral sparganosis.
引文
[1]郭启勇.实用放射学[M].北京:人民卫生出版社,2007:173-174.
[2]Takeuchi K.A case with plerocercoid which is parasitic in the brain[J].Nippon Byoyi Gakkai Kaishi,1918,7:611-620.
[3]易先满,罗伟,刘军.脑裂头蚴病的MRI表现及相关病理改变[J].实用放射学杂志,2010,26(1):11-13.
[4]龚才桂,王小宜,刘慧,等.脑曼氏裂头蚴病的MRI诊断[J].中华放射学杂志,2006,40(9):913-917.
[5]Nishiyama T,Idc T,Himes S R,et al.Immunodiagnoses of human sparganosis mansoni by micro-chemilumiescence enzyme-linked immunosorbent assay[J].Trans R Soc Trop Med Hyg,1994,88(6):663-665.
[6]刘仁伟.脑裂头蚴的MRI诊断[J].实用放射学杂志,2014,30(2):349-351.
[7]罗昭阳.脑裂头蚴病的CT及MRI表现[J].中国医学影像学杂志,2013,21(3):169-172.
[8]潘锋,祝跃明,吴晓,等.脑曼氏裂头蚴病MRI特点及追踪观察[J].医学研究杂志,2013,42(5):173-176.
[9]吕铁,李克,陈宏.脑曼氏裂头蚴的特征性MRI表现[J].中国医学计算机成像杂志,2007,13(2):78-80.
[10]姜保东,吕铁,冯晓源,等.脑曼氏裂头蚴病的MRI特征[J].实用放射学杂志,2009,25(1):5-7.